Navigation Links
Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
Date:11/19/2012

ed and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources. The Securities Repurchase Program will terminate on November 14, 2013 or at such time as Valeant completes its purchases. The program does not require Valeant to repurchase a minimum number of securities, and the Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice. Valeant's Board of Directors believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.

On November 8, 2011, Valeant commenced its former securities repurchase program, which terminated on November 7, 2012. Under that securities repurchase program, the Company purchased 6,792,311 of its common shares for aggregate consideration of $345.8 million, a total of $2.4 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $7.9 million, a total of $34.5 million principal amount of its 6.50% Senior Notes due 2016 for aggregate consideration of $34.3 million, a total of $45.4 million principal amount of its 6.875% Senior Notes due 2018 for aggregate consideration of $45.0 million and a total of $10.0 million principal amount of its 7.00% Senior Notes due 2020 for aggregate consideration of $9.5 million.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valea
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
2. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
3. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
4. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
5. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
6. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
7. Valeant Pharmaceuticals To Syndicate Incremental Loans
8. Valeant Pharmaceuticals Announces Management Change
9. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
10. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
11. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... Oct. 22, 2014  Cephasonics, a technology-innovation leader with ... the cQUB™-1 (cQuest Ultrasound Box™-1), the first product in ... and manufactured by Cephasonics for purchase by companies to ... Cephasonics will be showcasing the cQUB-1 for the first ... in Chongqing, China from October ...
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... causes common cold sores -- herpes simplex -- might increase ... suggest. In fact, being a carrier of certain antibodies ... the researchers found. "The identification of a treatable ... a breakthrough," said lead researcher Dr. Hugo Lovheim, an associate ...
(Date:10/25/2014)... THURSDAY, Oct. 23, 2014 (HealthDay News) -- A large ... West Africa is to avoid tens of thousands of ... Yale University researchers predict. Using a specially ... future of the outbreak in just one densely populated ... the capital city of Monrovia. The researchers said ...
(Date:10/25/2014)... -- October,s shorter, darker days can trigger a type ... an expert. People affected by seasonal affective ... motivation and even have trouble getting out of bed. ... Dr. Angelos Halaris, a professor in the department of ... School of Medicine. "Seasonal affective disorder should not ...
(Date:10/22/2014)... 22, 2014 On October 22, CBS ... featuring skin diseases both fictional and real. The ... nonprofit organization committed to advocacy and philanthropy in the ... take the opportunity to impart truth and clarity about ... There are many misconceptions about Morgellons Disease ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... -- Patients who undergo angioplasty to unblock a clogged ... in a cardiac rehabilitation program afterwards, researchers report. ... are significant given the fact that more than 600,000 ... according to the American Heart Association (AHA). In ...
... Randy Dotinga HealthDay Reporter , MONDAY, May 16 (HealthDay ... infested by parasites despite clinical evidence to the contrary. Now, ... in the patient,s head -- is often right on target. ... bugs, worms or germs had invaded their skin. In all but ...
... broadly support a strong commitment to medical and health ... and the state,s and the nation,s economy, according to ... Research!America and Northeast Ohio Medical University (NEOMED). ... health research is important42% say very importantto the state,s ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... control attention deficit hyperactivity disorder appear to be at ... taking ADHD medications, a new study finds. "ADHD ... might be expected to increase the risk of cardiovascular ...
... and Medicine announce Health System Reform in ... which focuses on the health system reforms Asian ... rapid economic, social, demographic and epidemiologic change in ... social science scholars, policymakers and professionals working in ...
... , MONDAY, May 16 (HealthDay News) -- The ... United States is strongly associated with a local area,s ... facilities provide end-of-life care that can improve pain control, ... lead author Dr. Maria Silveira, of the Veterans Affairs ...
Cached Medicine News:Health News:Cardiac Rehab Can Boost Survival After Angioplasty, Study Finds 2Health News:For Some, Bugs Crawling on Skin Is a Delusion 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 3Health News:Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study 2Health News:Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study 3Health News:Elsevier Health System Reform in Asia Conference 2Health News:Hospice Care More Common in Wealthier Areas, Study Finds 2
Designed to remove cell debris or tissue remnants from the retina....
... The Medtronic Model 6495 Bipolar Coaxial Temporary ... advantages of bipolar technology based on the ... Model 6500 Unipolar Temporary Pacing Lead., ,The ... provide consistent temporary sensing and pacing during ...
... presents the Streamline family of temporary sensing ... the gold standard in temporary pacing leads ... them easy to use and less traumatic ... Pacing Leads are designed to provide consistent ...
... assist device was designed specifically to obviate ... aorta. The eNcloseII device can provide the ... dramatically better hemodynamics as compared to partial ... have suggested that complete or partial clamping ...
Medicine Products: